Between April 2002 and July 2003, 20 patients with hematological malignancies or metastatic solid tumors received an RIC allo-SCT from an HLA identical sibling in a pilot study assessing the impact of ...
Delayed-onset, grade IV neutropenia associated with rituximab therapy in a lymphoma patient: A case report and literature review No significant financial relationships to disclose. This is an ASCO ...
HOUSTON - Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from ...
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1) In a phase III, US intergroup ...
Company will issue ordinary shares and pay $10 million upon successful Phase II trial of rHuEPO. XTL Biopharmaceuticals entered into an asset purchase agreement with Bio-GAL for the rights to a use ...
In most Hereditary Spherocytosis (HS) affected newborns, transient transfusion need correlates with a poor erythroid response to anemia, as illustrated by reticulocyte counts inappropriately low for ...
In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...
Erythropoietin treatment improves brain function, neuropsychological test scores, and electroencephalography measurements in patients with CKD. Both chronic kidney disease (CKD) and anemia may ...
Erythropoietin was no help for newborns with hypoxic-ischemic encephalopathy already undergoing therapeutic hypothermia in the phase III HEAL trial. Combined death or neurodevelopmental impairment by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results